<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319382</url>
  </required_header>
  <id_info>
    <org_study_id>P091202</org_study_id>
    <nct_id>NCT02319382</nct_id>
  </id_info>
  <brief_title>Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET</brief_title>
  <acronym>INFLAPARK</acronym>
  <official_title>High Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>France Parkinson Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is accumulating evidence suggesting that inflammatory processes, through microglial&#xD;
      activation, would play a key role in the neurodegenerative process of Parkinson's disease&#xD;
      (PD). It is considered that microglial activation would be part of self-propelling cycle of&#xD;
      neuroinflammation that fuels the progressive dopaminergic neurodegeneration. It is however&#xD;
      hard to evidence microglial activation in vivo, especially in the substantia nigra: first,&#xD;
      the investigators need very high resolution imaging tools and then, the only ligand available&#xD;
      to date, 11C-PK11195, has a low sensitivity and specificity and provided heterogeneous&#xD;
      results.&#xD;
&#xD;
      18F-DPA-714 is a new PET ligand which labels microglial cells. The investigators aim to&#xD;
      explore the topography and intensity of microglial activation in several different groups of&#xD;
      PD patients: 1) de novo, drug-naïve subjects (n = 6); 2) non-fluctuating treated patients&#xD;
      (&quot;honeymoon&quot;) (n = 10); 3) advanced drug-responsive patients motor fluctuations (wearing-off&#xD;
      or dyskinesia) (n = 6); 4) patients with LRRK2 gene mutation (n = 6); and 5) related to&#xD;
      healthy patients carriers of the mutation LRRK2(n = 6). PET imaging will be performed with a&#xD;
      new generation tomography having a very high resolution.&#xD;
&#xD;
      This study might reveal significant neuroinflammatory process in the midbrain of PD patients&#xD;
      and will determine if such process is present in both sporadic and genetic forms of PD. The&#xD;
      results of this study might provide a new biomarker of disease pathological progression and&#xD;
      help as identifying subjects who might most benefit from a specific anti-inflammatory drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accumulation of [18F]DPA-714 in the midbrain assessed through PET</measure>
    <time_frame>Inclusion visit</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Parkinson's Disease With LRRK2 Mutation</condition>
  <condition>Healthy Controls</condition>
  <condition>Parkinson's Disease Without LRRK2 Mutation</condition>
  <arm_group>
    <arm_group_label>2 markers: 18F-DPA-714 and 11C-PE2I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET with the tracer 18F-DPA-714</intervention_name>
    <arm_group_label>2 markers: 18F-DPA-714 and 11C-PE2I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET with the tracer 11C-PE2I</intervention_name>
    <arm_group_label>2 markers: 18F-DPA-714 and 11C-PE2I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic field</description>
    <arm_group_label>2 markers: 18F-DPA-714 and 11C-PE2I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
        The subject is an out-patient aged 18 years or above Active affiliation to national health&#xD;
        insurance system Signed informed consent to participate in the study&#xD;
&#xD;
        Additional criteria depending on the group under study:&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
        Parkinson disease diagnosed for less than 18 months and no treatment Age at disease over 40&#xD;
        years&#xD;
&#xD;
        Group 2:&#xD;
&#xD;
        Disease Parkinson diagnosed for less than 36 months and treated by L-Dopa or /and&#xD;
        dopaminergic agonist No motor fluctuation Age at disease over 40 years&#xD;
&#xD;
        Group 3:&#xD;
&#xD;
        Parkinson disease diagnosed for more than 3 years Age at disease over 40 years Motor&#xD;
        fluctuations for more than 6 months (dyskinesia or wearing off )&#xD;
&#xD;
        Group 4:&#xD;
&#xD;
        Parkinson disease LRRK2 mutation proved by genetic analysis&#xD;
&#xD;
        Group 5:&#xD;
&#xD;
        LRRK2 mutation proved by genetic analysis No evidence of Parkinson disease attested by a&#xD;
        Unified Parkinson's Disease Rating Scale (UPDRS) score of 0 or1&#xD;
&#xD;
        Group 6:&#xD;
&#xD;
        No evidence of Parkinson disease attested by a UPDRS score of 0 or1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
        Contraindication for MRI Anti-inflammation treatment for more 50 days during previous year&#xD;
        or for more 7 days during previous month Pregnancy or lactating Legal incapacity or limited&#xD;
        legal capacity Beneficiary of AME&#xD;
&#xD;
        Additional criteria depending on the group under study:&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
        Atypical parkinsonism Other neurological diseases or known brain lesion&#xD;
&#xD;
        Group 2:&#xD;
&#xD;
        Atypical parkinsonian syndrome&#xD;
&#xD;
        Group 3:&#xD;
&#xD;
        Atypical parkinsonian syndrome Resistance to treatment (benefit of treatment estimated to&#xD;
        less than 30%) Other neurological diseases or known brain lesion&#xD;
&#xD;
        Groups 4 and 5:&#xD;
&#xD;
        Other neurological diseases or known brain lesion&#xD;
&#xD;
        Group 6:&#xD;
&#xD;
        Previous neurological or psychiatry diseases or known brain lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe REMY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe REMY, MD, PhD</last_name>
    <phone>(0)1.69.86.77.27</phone>
    <phone_ext>+33</phone_ext>
    <email>neuro-philippe.remy@hmn.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia LAVISSE, PhD</last_name>
    <phone>(0)1.69.86.78.91</phone>
    <phone_ext>+33</phone_ext>
    <email>sonia.lavisse@cea.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orsay Hospital</name>
      <address>
        <city>Orsay</city>
        <zip>91401</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe REMY, MD PhD</last_name>
      <phone>(0)1.69.86.77.27</phone>
      <phone_ext>+33</phone_ext>
      <email>neuro-philippe.remy@hmn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sonia LAVISSE, PhD</last_name>
      <phone>(0)1.69.86.78.91</phone>
      <phone_ext>+33</phone_ext>
      <email>sonia.lavisse@cea.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>[18F]DPA-714</keyword>
  <keyword>Positron emission tomography (PET)</keyword>
  <keyword>Neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

